Overview

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Status:
Active, not recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.
Phase:
Phase 1
Details
Lead Sponsor:
Acetylon Pharmaceuticals Incorporated
Celgene
Treatments:
Antibodies, Monoclonal
Nivolumab